

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.webjo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/528,150	03/17/2005	Takeshi Kawazoe	2005_0459A	2807		
513 WENDEROT	7590 07/01/200 H. LIND & PONACK, 1	EXAM	EXAMINER			
1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503			JAVANMA	JAVANMARD, SAHAR		
			ART UNIT	PAPER NUMBER		
		1617				
			MAIL DATE	DELIVERY MODE		
			07/01/2009	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/528,150	KAWAZOE ET AL.		
Examiner	Art Unit		
SAHAR JAVANMARD	1617		

	SAHAR JAVANMARD	1617					
The MAILING DATE of this communication appe	ears on the cover sheet with the o	correspondence add	ress				
THE REPLY FILED 26 May 2009 FAILS TO PLACE THIS APP	LICATION IN CONDITION FOR AL	LOWANCE.					
 M The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of App for Continued Examination (RCE) in compliance with 37 C 	replies: (1) an amendment, affidavi	t, or other evidence, v with 37 CFR 41.31; o	hich places the (3) a Request				
	The period for reply expires <u>3</u> months from the mailing date of the final rejection.						
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is late no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b), ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN							
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filled is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL.	tension and the corresponding amount of shortened statutory period for reply origing than three months after the mailing date	of the fee. The appropri- nally set in the final Office	ate extension fee e action; or (2) as				
The Notice of Appeal was filed on A brief in comp	liance with 37 CFR 41.37 must be t	iled within two month	s of the date of				
filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed w	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the					
<u>AMENDMENTS</u>							
 The proposed amendment(s) filed after a final rejection, I 			cause				
(a) They raise new issues that would require further con		E below);					
(b) They raise the issue of new matter (see NOTE belo							
 (c) They are not deemed to place the application in bet appeal; and/or 	ter form for appeal by materially red	lucing or simplifying t	ne issues for				
(d) They present additional claims without canceling a	corresponding number of finally reig	ected claims					
NOTE: (See 37 CFR 1.116 and 41.33(a)).	sorresponding number of finally reje	oted ciairris.					
4. The amendments are not in compliance with 37 CFR 1.11	21 See attached Notice of Non-Co	mnliant Amendment (DTOL-324)				
Applicant's reply has overcome the following rejection(s)		inpliant Americanient (101-324).				
Newly proposed or amended claim(s) Would be all		imalı filad amandına	st concelling the				
non-allowable claim(s).	owable ii subiliitted iii a separate, t	intery fried afficialmen	it canceling the				
 For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proving. 		be entered and an e	xplanation of				
The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed:							
Claim(s) objected to:							
Claim(s) rejected:							
Claim(s) withdrawn from consideration:							
AFFIDAVIT OR OTHER EVIDENCE	thefere are the date of fire a blo		ha antonia				
 The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 							
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to c showing a good and sufficient reasons why it is necessar 	vercome <u>all</u> rejections under appea	l and/or appellant fail	s to provide a				
10. The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER							
Name of the request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.							
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).							
13. ☑ Other: References in IDS of 5/26/09 have been consider							
/SREENI PADMANABHAN/	/S. J./						
Supervisory Patent Examiner, Art Unit 1617	Examiner, Art Unit 1617						

Continuation of 11, does NOT place the application in condition for allowance because: Applicant's arguments are not persuasive. First, Applicant contends that the stage for treating levicid or scar is completely different between the instant invention and the C.S reference. This argument is not persuasive because it is not commensurate in scope of the claimed invention. There is no limitation set forth in the claims that the wound must be "open" as set forth in Applicant's arguments. Sepecifically, the dailins recite" an obuse of therapy of wound or dermal injury..., which in Examiner's opinion includes a wound that is healed. It is near the end of the course of dermal injury, Additionally, Applicant continues to argue that the C.S reference does not teach "topical application" of acetylsalicylic aid. This argument is not persuasive because it is not commensurate in scope of the claimed invention. As set forth in the claims, there is no limitation as to the route of administration of the acetylacetic acid, therefore, the teachings of C.S read on the instant claims.